Konsume
Interval Day Week Month
Range 30 Day 90 Day 6 Months 1 Yr
Newswire Search Past 90 Days 9 stories 4 Publishers
Trending Today
Sort By: Snapshot
Buzz
Media Coverage
World View
Related Topics
Topic # Mentions Topic Reach
ivonescimab5-
positive5-
survival3-
nsclc3-
Prominent Journalists
Byline Articles Written Avg Reach
by PR Newswire 4 -
RTTNews Staff Writer 3 -
By Salong Debbarma 1 -
Meghana Keshavan 1 -


Akeso Announces First Patient Enrolled in Global Phase III Trial of Cadonilimab Versus Nivolumab in First-Line Gastric Cancer
by PR Newswire — thailand-business-news.com


Akeso Reports Positive Overall Survival Results For Ivonescimab In First-Line PD-L1-Positive NSCLC
RTTNews Staff Writer — rttnews.com


Ivonescimab Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC: Positive Overall Survival Results from HARMONi-2 Presented at WCLC 2026
by PR Newswire — thailand-business-news.com


Ivonescimab Meets Overall Survival Key Secondary Endpoint in Interim Analysis of Phase III HARMONi-2 Study, Demonstrating Statistically Significant and Clinically Meaningful Benefit Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC
by PR Newswire — thailand-business-news.com


Akeso 2026 Interim Results: Strong Commercialization Momentum; IO2.0+ Global Strategy Redefining Clinical Standards; Bispecific Advancement in ADC, I&I and Alzheimer's
by PR Newswire — thailand-business-news.com


Summit Therapeutics Stock Rises 8%
RTTNews Staff Writer — rttnews.com


Akeso and Summit's lung cancer drug shows worsening tumor-progression benefit
Meghana Keshavan — statnews.com


Akeso secures China NMPA authorisation for ivonescimab combo
By Salong Debbarma — pharmaceutical-business-review.com


Akeso's SNDA For Ivonescimab + Chemotherapy Combo Gets Approval From China's NMPA, Stock Up
RTTNews Staff Writer — rttnews.com

Execution: 2.57 Seconds. 31.81 mb used.